# A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

> **NCT05917938** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 33 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** NNC0194-0499

## Key facts

- **NCT ID:** NCT05917938
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-04
- **Primary completion:** 2024-12-16
- **Final completion:** 2024-12-16
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05917938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05917938, "A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05917938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*